Takeda Pharmaceutical Company Limited (NYSE:TAK) Stock Position Increased by Two Sigma Advisers LP

Two Sigma Advisers LP lifted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 367.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 154,600 shares of the company's stock after purchasing an additional 121,500 shares during the quarter. Two Sigma Advisers LP's holdings in Takeda Pharmaceutical were worth $2,047,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in TAK. Farther Finance Advisors LLC increased its position in Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after buying an additional 1,976 shares during the period. Crowley Wealth Management Inc. acquired a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at approximately $52,000. Cromwell Holdings LLC bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $61,000. Venturi Wealth Management LLC boosted its position in shares of Takeda Pharmaceutical by 554.7% during the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after buying an additional 4,260 shares during the period. Finally, Lindbrook Capital LLC boosted its position in shares of Takeda Pharmaceutical by 65.0% during the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock worth $68,000 after buying an additional 2,029 shares during the period. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK traded up $0.21 during trading hours on Friday, reaching $15.01. 1,725,292 shares of the company's stock traded hands, compared to its average volume of 1,937,971. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.43. The business's fifty day simple moving average is $14.66 and its two-hundred day simple moving average is $14.04. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The firm has a market capitalization of $47.76 billion, a price-to-earnings ratio of 37.53, a P/E/G ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The company had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.